Patients with high-risk melanoma had better quality of life on pembrolizumab than on standard immunotherapy regimens


Patients with high-risk stage III-IV melanoma who received pembrolizumab after their surgery reported a better quality of life than patients who received the previous standard-of-care treatment with either ipilimumab or high-dose interferon. These findings were from a large clinical trial led by the SWOG Cancer Research Network and are reported in the journal JAMA Oncology.

Researchers discover existing drug can disrupt coronavirus replication

Previous article

Remote Employee Onboarding: 5 Steps to Success

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations